Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?
Related Questions
How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?
How do you approach patients with malignant melanoma who are disease free on immunotherapy for over 3 years?
How do you approach patients with stage III melanoma for adjuvant treatment?
How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
How do you approach a patient with recurrent chest wall BRAF(+) mutated melanoma who developed multiple metastatic axillary nodes while on immunotherapy, now post axillary dissection for adjuvant radiation?
How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?
